Developments in the Pharmaceuticals Industry

China’s pharmaceuticals industry is one of the industries making use of foreign funds and running three kinds of foreign-funded enterprises from an early date. In 1980, it signed a contract with the Japanese Pharmaceu-tical Enterprise to establish the China Otsuka Pharmaceuticals Co. Ltd.---the first joint venture in China’s pharma-ceuticals industry. According to incom-

Countermeasures and Suggestions for Strengthening Human Resource Management in China’s Pharmaceutical Industry

Objective To provide reference and enlightenment for the development of human resource management in China’s pharmaceutical industry and to put forward some suggestions to promote the further development of pharmaceutical industry.Methods The method of literature review was used to analyze the current situation and existing problems of human resource management in China’s pharmaceutical industry.Results and Conclusion Only by continuously improving the human resource management skills and innovating management methods can pharmaceutical enterprises achieve long-term benefits with sustainable development.The formulation of human resource management strategy in pharmaceutical industry must be conducive to the realization of the business goals of enterprises.To achieve this overall goal,the human resources management department of enterprises must make the plan from a strategic perspective,formulate talent strategic planning which serves the overall strategic goal of the enterprise.As a result,human resource management will play an important role in the development of China’s pharmaceutical industry.

Optimization of a Method for the Simultaneous Determination of Phloroglucinol and Trimethylphloroglucinol by High Performance Liquid Chromatography in Routine Use in a Pharmaceutical Industry in Abidjan

In order to provide the population with safe, effective and good quality medicines, the pharmaceutical industries, before releasing batches of their products into the pharmaceutical circuit, put in place internal dosage methods to control the quality of these products. The present study consisted in optimizing a method for the simultaneous determination of Phloroglucinol (PHG) and Trimethylphloroglucinol (TPH) by high performance liquid chromatography (HPLC) routinely used in a pharmaceutical industry located in a township in Abidjan (Ivory Coast). The basic chromatographic conditions were those routinely used for the determination of these two molecules: mobile phase: acetonitrile/water (60/40), stationary phase (C18 BDS Hypersil 250 mm * 4.6 mm - 5 μm), detection wavelength (265 nm), flow rate, injection volume and run time configured at the equipment level were respectively 1 mL/min, 10 μL and 8 min. The method of preparation of the analytes (PHG and TPHG) was also applied by the pharmaceutical industry. The application of these different parameters at the equipment level made it possible to determine a chromatogram which highlights three chromatographic peaks with respective retention times (RT) of 0.773 min (unidentified compound), 2.275 min (PHG) and 7.269 min for an analysis time of 8 min with a better resolution of the peaks and baseline. The progressive optimization of different parameters such as the stationary phase (C18 YMC 150 mm * 4.6 mm - 3 μm), the proportion of the mobile phase: acetonitrile/water (80/20), the flow rate impelled by the pump (0.8 mL/min) and the modification of the analyte preparation mode (same amount of PHG and TPHG in a 50 mL volumetric flask) resulted in a final chromatogram that highlighted two chromatographic peaks at the respective RT of 2.391 min (PHG) and 3.735 min (TPHG) at a run time of 6 min. The chromatographic conditions that led to the final chromatogram can be used routinely by the pharmaceutical industry for the determination of several PHG and TPHG drug matrices after prior validation of the determination method.

Research on the Impact of Independent R&D and Collaborative Innovation on Economic Performance in China’s pharmaceutical Industry

Objective To study the impact of independent R&D and collaborative innovation on economic performance in the pharmaceutical industry.Methods A panel regression model was established by selecting the panel data of China’s pharmaceutical industry from 2009 to 2019.Results and Conclusion Independent R&D and collaborative innovation of the pharmaceutical industry in eastern,central and western regions of China had a positive effect on economic performance.Besides,the promotion effect of independent R&D was greater than that of collaborative innovation.The positive driving effect of economic performance is the largest among the three regions,followed by the central and western regions.The collaborative innovation has the greatest positive effect on economic performance in the central region,followed by the eastern and western regions.

Research on the Threshold Effect of China’s Pharmaceutical Export Trade on Internal and External R&D Investment

Objective To study the threshold effect of export trade on internal and external R&D investment in China’s pharmaceutical industry,and to provide reference for some pharmaceutical enterprises to improve the investment.Methods The panel data of pharmaceutical industry in 25 provinces and cities in China from 2009 to 2019 were selected to conduct empirical analysis by establishing a threshold regression model,and a better export trade interval was obtained.Results and Conclusion There is a threshold value for the effect of new product export on both internal and external R&D expenditures,and the threshold values are 845.2788 million yuan and 318.4198 million yuan,respectively.There is a single threshold effect of export trade on both internal and external R&D investment in China’s pharmaceutical industry,and the effect of export trade on internal and external R&D investment changes from negative to positive as the export trade develops from low to high.

Research on the Relationship between Export Orientation and R&D Investment of China’s Pharmaceutical Industry in Different Regions

Objective To study the relationship between export orientation and research and development(R&D)investment so as to provide suggestions and references for improving the R&D investment level and innovation capabilities of pharmaceutical industry due to the progress of globalization and the continuous development of export trade of China’s pharmaceutical industry.Methods The relevant data of China’s pharmaceutical industry from 2001 to 2016 was selected to establish an error correction model based on the co-integration theory,and then the Granger causality test was conducted to determine the relationship between the export orientation and R&D investment of China’s pharmaceutical industry in different regions.Results and Conclusion It is found that the export orientation of the pharmaceutical industry in different regions has a significant negative impact on the investment of R&D.Among them,the middle region has the greatest impact,followed by the eastern and western regions.The export orientation of the pharmaceutical industry in the middle region has a lag effect on R&D investment,and the lag phase is two years.

PROSPECTS OF CHINA'S PHARMACEUTICAL INDUSTRY

Director-general of the StateAdministration of Medicines ZhengXiaoyu gave an interview recently onthe development of China’s medicines in the9th Five-Year Plan period(1996-2000) andthe long-term development programme upto 2010.

Research on the Relationship between Cooperation Innovation Expenditure and Economic Output of China’s Pharmaceutical Industry

Objective To empirically analyze the relationship between cooperation innovation expenditure and economic output of China’s pharmaceutical industry,and provide a reference for improving its economic benefits and the capability of cooperation innovation in the future.Methods The relevant data of China’s pharmaceutical industry from 2000 to 2016 was selected as a sample.Based on the co-integration theory,an error correction model was established to conduct Granger test of causality to study the relationship between cooperation innovation expenditure and economic output of China’s pharmaceutical industry.Results and Conclusion The cooperation innovation expenditure of China’s pharmaceutical industry has a significant positive impact on economic output.If cooperation innovation expenditure increases 1%,its economic output will go up by 1.7%.At the same time,the long-term promotion effect of cooperation innovation expenditure on economic output is more significant than the short-term effect.

Research on the Relationship between Salary Incentives for R&D Personnel and R&D Investment in China’s Pharmaceutical Industry

Objective To explore the relationship between salary incentives for R&D personnel and R&D investment in China’s pharmaceutical industry through an empirical analysis so as to propose suggestions for increasing more R&D investment from the perspective of stimulating R&D personnel.Methods Based on the relevant data of the China’s pharmaceutical industry in the“China High-tech Industry Statistical Yearbook”and other data from the National Bureau of Statistics from 1995 to 2018,co-integration tests was used to construct error correction models and Granger causality tests to explore the relationship between R&D personnel salary incentives and R&D investment.Results and Conclusion There is a long-term balanced relationship between the salary level of R&D personnel in China’s pharmaceutical industry and the investment of R&D.For the per capita salary of R&D personnel increases by 1 unit,the internal expenditure of R&D investment will increase by 2.2451 units.In the short term,the per capita salary of R&D personnel has a slight negative impact on the internal expenditure of R&D investment.In addition,the salary incentives for R&D personnel have the most significant role in promoting R&D investment after five years of implementation.

Comparative Study and Enlightenment on Innovation Achievements of Pharmaceutical Industry in Liaoning Province

Objective To promote the innovation and development of pharmaceutical industry in Liaoning Province.Methods Literature study and comparative study were used to investigate the current situation and problems of innovation-driven development of pharmaceutical industry in Liaoning Province by comparing data of Heilongjiang,Jilin,Shandong,and Jiangsu from four aspects of priority review and approval,consistency evaluation of generic drugs,new drugs on the market,and scientific and technological innovation achievements.Results and Conclusion In terms of innovation-driven development,pharmaceutical industry in Liaoning Province has the following problems,such as small scale,weak transformation of scientific and technological achievements,tough business environment,and single platform module of scientific and technological achievements.Combined with the actual development of pharmaceutical industry in Liaoning province,the government should give full play to its leading role and guide“Benxi Pharmaceutical Capital”to establish characteristic industrial cluster and incubation park.After high quality enterprises and high-level innovative talents get together,enterprises can analyze their actual situation to plan R&D layout,focusing on the input-output ratio.Meanwhile,the benign development of the enterprises,universities and research institutes should be promoted to integrate technical innovation and product supply.This can enhance the cooperation among the government,enterprise,university,and research institute,and provide reference for further development of pharmaceutical industry in Liaoning province.

上海药物研发行业职业健康管理现状与改进策略

目的 了解上海药物研发行业职业健康管理现状及面临的挑战,为制订行业职业健康管理策略,促进行业健康发展提供参考。方法 采用问卷调查法对上海48家药物研发公司的职业健康风险、管理现状及存在的问题进行梳理,采用现场调研法对5家代表性公司实地了解行业职业危害防护和新业态的管理需求,探讨可行的解决方案。结果 问卷调查结果显示半数以上的药物研发公司从事小分子药物和抗肿瘤药物研发,面临着研发试剂、研发中的药物、病原微生物和实验动物等多重健康风险。职业病防护设施“三同时”工作完成率为43.8%,职业病危害因素检测和职业健康监护的开展率分别为89.6%和79.2%。现场调研发现药物研发行业的建筑通风、职业危害防护以及新业态的职业健康管理面临挑战。结论 随着药物研发行业的快速发展,潜在职业健康风险不容忽视,职业危害防护和管理工作亟待细化和完善。

Leveraging Blockchain with Optimal Deep Learning-Based Drug Supply Chain Management for Pharmaceutical Industries

Due to its complexity and involvement of numerous stakeholders,the pharmaceutical supply chain presents many challenges that companies must overcome to deliver necessary medications to patients efficiently.The pharmaceutical supply chain poses different challenging issues,encompasses supply chain visibility,cold-chain shipping,drug counterfeiting,and rising prescription drug prices,which can considerably surge out-of-pocket patient costs.Blockchain(BC)offers the technical base for such a scheme,as it could track legitimate drugs and avoid fake circulation.The designers presented the procedure of BC with fabric for creating a secured drug supplychain management(DSCM)method.With this motivation,the study presents a new blockchain with optimal deep learning-enabled DSCM and recommendation scheme(BCODL-DSCMRS)for Pharmaceutical Industries.Firstly,Hyperledger fabric is used for DSC management,enabling effective tracking processes in the smart pharmaceutical industry.In addition,a hybrid deep belief network(HDBN)model is used to suggest the best or top-rated medicines to healthcare providers and consumers.The spotted hyena optimizer(SHO)algorithm is used to optimize the performance of the HDBN model.The design of the HSO algorithm for tuning the HDBN model demonstrates the novelty of the work.The presented model is tested on the UCI repository’s open-access drug reviews database.

An Extensive Study and Review of Privacy Preservation Models for the Multi-Institutional Data

The deep learning models hold considerable potential for clinical applications, but there are many challenges to successfully training deep learning models. Large-scale data collection is required, which is frequently only possible through multi-institutional cooperation. Building large central repositories is one strategy for multi-institution studies. However, this is hampered by issues regarding data sharing, including patient privacy, data de-identification, regulation, intellectual property, and data storage. These difficulties have lessened the impracticality of central data storage. In this survey, we will look at 24 research publications that concentrate on machine learning approaches linked to privacy preservation techniques for multi-institutional data, highlighting the multiple shortcomings of the existing methodologies. Researching different approaches will be made simpler in this case based on a number of factors, such as performance measures, year of publication and journals, achievements of the strategies in numerical assessments, and other factors. A technique analysis that considers the benefits and drawbacks of the strategies is additionally provided. The article also looks at some potential areas for future research as well as the challenges associated with increasing the accuracy of privacy protection techniques. The comparative evaluation of the approaches offers a thorough justification for the research’s purpose.

The Development and Experience of American Pharmaceutical Industry Associations and Its Enlightenment to China

Objective To study the development history and current situation of pharmaceutical industry associations in the United State and to provide reference for China’s pharmaceutical industry associations.Methods Literature research and comparative study were used to investigate the development history and current situation of pharmaceutical associations in the United States.Then,their characteristics and experiences were summarized.Some countermeasures and suggestions were put forward for the existing problems of pharmaceutical associations in China.Results and Conclusion The institutional environment of pharmaceutical associations in the United States is relatively good,reflecting the characteristics of emphasizing process management and neglecting entrance management with and the help of public supervision.At the same time,the government advocates market competition by adhering to the market-oriented services for the public.American pharmaceutical industry associations have strong innovation capacity and perfect credit system.Drawing on the experience of pharmaceutical industry associations in the United States,China should strengthen the construction of pharmaceutical industry associations.Firstly,the supervision mechanism should be improved.Secondly,these associations should have good partnerships with the government and offer the public the best services.Finally,the fund-raising mechanism of pharmaceutical industry associations should be optimized to ensure the innovative development of the pharmaceutical industry.

Underestimated contribution of fugitive emission to VOCs in pharmaceutical industry based on pollution characteristics, odorous activity and health risk assessment

Fugitive emission has been becoming an important source of volatile organic compounds(VOCs) in pharmaceutical industry,but the exact contribution of fugitive emission remains incompletely understood.In present study,pollution characteristics,odorous activity and health risk of stack and fugitive emissions of VOCs from four functional units (e.g.,workshop,sewage treatment station,raw material storage and hazardous waste storage) of three representative pharmaceutical factories were investigated.Workshop was the dominant contributor to VOCs of fugitive emission in comparison with other functional units.Extreme high concentration of VOCs from fugitive emission in unsealed workshop (94.87 mg/m^(3))was observed relative to sealed one (1.18 mg/m^(3)),accounting for 31%and 5%of total VOCs,respectively.Fugitive emission of VOCs in the unsealed workshop mainly consisted of nhexane,1-hexene and dichloromethane.Odorous activity indexes and non-cancer hazard ratios of these VOCs from fugitive emission in the unsealed workshop were as high as that from stack exhaust.Furthermore,cancer risk of dichloromethane from fugitive emission and stack exhaust was up to (1.6-1.8)×10^(-5).Odorous activity or health risk index of the VOCs from fugitive emission was up to 13 or 11 times of the corresponding threshold value,posing remarkable health threat on pharmaceutical workers.Our?ndings highlighted the possibly underestimated contribution of fugitive emission on VOCs in the pharmaceutical industry.

Gauging a Firm's Innovative Performance Using an Integrated Structural Index for Patents

Purpose： In this contribution we try to find new indicators to measure characteristics of a finn＇s patents and their influence on a company＇s profits. Design/methodology/approach： We realize that patentevaluation and influence on a company＇s profits is a complicated issue requiring different perspectives. For this reason we design two types of structural h-indices, derived from the International Patent Classification （IPC）. In a case study we apply not only basic statistics but also a nested case-control methodology. Findings： The resulting indicator values based on a large dataset （19,080 patents in total） from the pharmaceutical industry show that the new structural indices are significantly correlated with a firm＇s profits. Research limitations： The new structural index and the synthetic structural index have just been applied in one case study in the pharmaceutical industry. Practical implications： Our study suggests useful implications for patentometric studies and leads to suggestions for different sized firms to include a healthy research and development （R＆D） policy management. The structural h-index can be used to gauge the profits resulting from the innovative performance of a firm＇s patent portfolio. Originality/value： Traditionally, the breadth and depth of patents of a firm and their citations are considered separately. This approach, however, does not provide an integrated insight in the major characteristics of a firm＇s patents. The Sh（Y） index, proposed in our investigation, can reflect a firm＇s innovation activities, its technological breadth, and its influence in an integrated way.

New medical reform and the sustainable development of the pharmaceutical industry in China

The national economy development and the demanding of the drugs request the pharmaceutical industry in China to keep sustainable development especially under the background of the new medical reform. According to the status of industry development and drug consumption in China, the trend and the driving factors for pharmaceutical industry in the future were estimated. Based on the analysis of the background and conditions for pharmaceutical industry sustainable development in China, the problems and challenges, the goal as well as the main measures for the sustainable development of pharmaceutical industry were put forward.

Pharmaceutical effluent evokes superbugs in the environment:A call to action

Antimicrobial resistance(AMR)is a growing global threat,especially in low-and middle-income countries(LMICs),causing prolonged illnesses,heightened antimicrobial use,increased healthcare expenses,and avoidable deaths.If not tackled,AMR could force 24 million people into severe poverty by 2030 and hinder progress on Sustainable Development Goals(SDGs).AMR spreads through interconnected ecosystems,with humans,animals,and the environment serving as reservoirs.Pharmaceutical wastewater,loaded with antibiotics and resistance genes,poses a significant environmental risk,mainly due to inadequate treatment and irresponsible disposal.The pharmaceutical industry is a notable contributor to environmental antibiotic pollution,with varying effluent management practices.Contaminated pharmaceutical wastewater discharge harms water sources and ecosystems.Urgent collaborative efforts are needed across policymakers,regulators,manufacturers,researchers,civil society,and communities,adopting a One Health approach to curb AMR's spread.Developing global standards for pharmaceutical effluent antibiotic residues,effective treatment methods,and improved diagnostics are vital in addressing AMR's environmental impact while safeguarding public health and the environment.National action plans should encompass comprehensive strategies to combat AMR.Preserving antibiotic efficacy and ensuring sustainable production require a united front from all stakeholders.